On August 27, 2023, BioLineRx Ltd. entered into a license agreement with Hong Seng Technology Limited and Guangzhou Gloria Biosciences Co., Ltd. pursuant to which the Company granted HST an exclusive, royalty-bearing, proprietary license with respect to the intellectual property rights and know-how associated with motixafortide (BL-8040) in order to develop and commercialize motixafortide in Asia (other than Israel and certain other countries) (collectively, the Territory") and to engage and authorize Gloria to perform services under the License Agreement in the Territory. The License Agreement provides that the Company will supply motixafortide to the Licensee during the term on a cost-plus basis for commercial supply, while supply for development purposes will be on a cost-plus basis except that in certain limited circumstances the supply will be at a reduced cost, with the Company bearing a portion of the cost to be applied against any future royalties. The Licensee has a right but not an obligation after the effective date of the License Agreement to manufacture motixafortide itself or through a designated party.

The License Agreement shall continue on a country-by-country basis in the Territory until the expiration or early termination of the royalty term. In addition, the License Agreement may be terminated by the Licensee at any time after payment of the upfront payment upon 90 days' prior written notice to the Company or upon the occurrence of special indemnity circumstances as described in the License Agreement. In addition, the License agreement may be terminated by either party in the case of a material breach or bankruptcy.

The License Agreement may also be terminated by either party prior to effectiveness date, if the IIA does not consent to the License Agreement or a party is exercising its right pursuant to the License Agreement to withhold agreement to modifications to the License Agreement as requested by the IIA. The License Agreement includes various development obligations for the Licensee pursuant to an agreed-upon development plan, including the execution of a registrational study in stem-cell mobilization and the execution of a randomized Phase 2/3 study in first-line pancreatic adenocarcinoma. In connection with the entry into the License Agreement, on August 27, 2023, the Company also entered into a securities purchase agreement with the Purchaser Party, pursuant to which the Company agreed to sell and issue in a private placement (the Private Placement") an aggregate of 6,829,137 American Depositary Shares (" ADSs"), each ADS representing fifteen ordinary shares, par value NIS 0.10, of the Company, at a purchase price of $2.136 per ADS.

In the event that BioLine wishes to grant a third party a license in relation to part or all of the rights under the License Technology or Jointly Owned Licensee's Development outside of the Territory for the Development and/or Commercialization of the Licensed Product substantially comparable in nature and scope to the terms of this Agreement, (herein, an Ex-Territory License Agreement"), prior to entering into negotiations with such third party, BioLine shall notify Licensee of BioLine's interest in proceeding with negotiations for such an Ex-Territory license Agreement (the First Offer Notice to Licensee). Licensee shall thereafter have days to consider whether it is interested in commencing negotiations with BioLine for the Ex-Territory License agreement further to the First Offer Notice to Licensee and, if it is, Licensee shall respond to BioLine in writing (the First Offer Response by Licensee). Upon receipt of the First Offer Response by Licensee, BioLine and Licensee shall engage in good faith negotiations to conclude the Ex-Territory license.

Should Licensee fail to provide the First Offer Response by Licenseo, BioLine and Licensee within the aforementioned day period or otherwise notifies BioLine that it is not interested in entering into the Ex-Territory licenses, or if, after Licensee provides the First Offer Response by Licensei, BioLine and Licensee, BioLine and licensee fail to execute the Ex-TerritoryLicense Agreement within the date the Ex-Territory Agreement within the Ex-Territory licence Agreement within the Ex-Terriory License Agreement within the date the ex-Territory License Agreement without any third party is provided, BioLine shall be free to the Ex-Territorylicense Agreement without any obligations to the Ex-Territories.